|
|
OSUCCC
 |
Clara D Bloomfield, M.D.
Professor
College of Medicine
Internal Medicine - Hematology/Oncology
519C James
300 West 10th Avenue Columbus,OH. 43210
o |
(614) 293-7518 |
f |
(614) 293-3132 |
|
Programs
|
 |
| After serving as director of the OSU Comprehensive Cancer Center from 1997 to July 2003, Dr. Bloomfield became Senior Advisor to the OSU cancer program and the charter member of the OSU Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of international stature.
Bloomfield is renowned for her more than three decades of research in adult leukemia and lymphoma, research that has been described in more than 600 publications and which has helped change standards of treatment.
Bloomfield earned her MD from the University of Chicago and completed training in internal medicine and medical oncology at the University of Minnesota, where she became a full professor in seven years.
In 1989 she became professor of medicine and chief of the Division of Oncology at the State University of New York at Buffalo, as well as chair of the Division of Medicine at Roswell Park Cancer Institute. She came to Ohio State in 1997, and in 2000 she was elected to the Institute of Medicine of the National Academy of Sciences.
At the OSUCCC, she serves as cancer scholar and senior adviser. She is also a member of the Molecular Biology and Cancer Genetics Program, a professor of internal medicine and holder of the William Greenville Pace III Endowed Chair in Cancer Research. |
|
Current Publications
|
|
Proc Natl Acad Sci U S A 106(31): 12950-5, 2009
|
|
Acquired copy number alterations in adult acute myeloid leukemia genomes.
|
|
Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrózek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, Dipersio JF, Ley TJ
|
|
|
in press: , 2009
|
|
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel,on behalf of the European LeukemiaNet.
|
|
Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD
|
|
|
Cancer Causes Control in press: , 2009
|
|
Low cancer incidence rates in Ohio Amish.
|
|
Westman JA, Ferketich AK, Kauffman RM, Maceachern SN, Wilkins JR 3rd, Wilcox PP, Pilarski RT, Nagy R, Lemeshow S, de la Chapelle A, Bloomfield CD
|
|
|
Best Pract Res Clin Haematol 22(2): 239-48, 2009
|
|
MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias.
|
|
Marcucci G, Mrózek K, Radmacher MD, Bloomfield CD, Croce CM
|
|
|
Blood 113(25): 6411-8, 2009
|
|
MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1.
|
|
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci G
|
|
|
Curr Opin Hematol 16(2): 64-9, 2009
|
|
Molecular signatures in acute myeloid leukemia.
|
|
Mrózek K, Radmacher MD, Bloomfield CD, Marcucci G
|
|
|
Haematologica 94(10): 1383-90, 2009
|
|
Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia.
|
|
Baldus CD, Thibaut J, Goekbuget N, Stroux A, Schlee C, Mossner M, Burmeister T, Schwartz S, Bloomfield CD, Hoelzer D, Thiel E, Hofmann WK
|
|
|
J Clin Oncol 27(19): 3198-204, 2009
|
|
Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Langer C, Marcucci G, Holland KB, Radmacher MD, Maharry K, Paschka P, Whitman SP, Mrozek, Baldus CD, Vij R, Powell BL, Carroll AJ, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD
|
|
|
Blood 114(5): 937-51, 2009
|
|
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
|
|
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD
|
|
|
Cancer 115(1): 84-93, 2009
|
|
Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803).
|
|
Grinblatt DL, Yu D, Hars V, Vardiman JW, Powell BL, Nattam S, Silverman LR, de Castro C 3rd, Stone RM, Bloomfield CD, Larson RA
|
|
|
Cancer Chemother Pharmacol 63(5): 859-64, 2008
|
|
A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.
|
|
Stone RM, Donohue KA, Stock W, Hars V, Linker CA, Shea T, Deangelo DJ, Marcucci G, Bloomfield CD, Larson RA, for the Cancer and Leukemia Group B
|
|
|
Semin Oncol 35(4): 324-5, 2008
|
|
Acute myeloid leukemia. Introduction.
|
|
Bloomfield CD, Marcucci G, Döhner K, Döhner H
|
|
|
Curr Opin Oncol 20(6): 711-8, 2008
|
|
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia.
|
|
Mrozek, Marcucci G, Paschka P, Bloomfield CD
|
|
|
Blood 112(10): 4193-201, 2008
|
|
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia.
|
|
Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Buchner T, Wormann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C
|
|
|
Int J Oncol 33(2): 239-44, 2008
|
|
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.
|
|
Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, Watson MS, Arthur DC, Tantravahi R, Heerema NA, Koduru PR, Block AW, Qumsiyeh MB, Edwards CG, Sterling LJ, Holland KB, Bloomfield CD
|
|
|
J Natl Cancer Inst Monogr (39): 52-7, 2008
|
|
Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia.
|
|
Mrózek K, Bloomfield CD
|
|
|
Blood 110(5): 1648-55, 2008
|
|
Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
|
|
Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ
|
|
|
Blood 112(5): 2013-6, 2008
|
|
DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
|
|
Whitman SP, Hackanson B, Liyanarachchi S, Liu S, Rush LJ, Maharry K, Margeson D, Davuluri R, Wen J, Witte T, Yu L, Liu C, Bloomfield CD, Marcucci G, Plass C, Caligiuri MA
|
|
|
Cancer Res 68(9): 3142-51, 2008
|
|
Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia.
|
|
Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, Blagitko-Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lubbert M, Marcucci G, Bloomfield CD, Plass C
|
|
|
Leuk Lymphoma 49(7): 1274-8, 2008
|
|
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
|
|
Wetzler M, Donohue KA, Odenike OM, Feldman EJ, Hurd DD, Stone RM, Westerfelt P, Bloomfield CD, Larson RA
|
|
|
Blood 111(3): 1552-9, 2008
|
|
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.
|
|
Whitman SP, Ruppert AS, Radmacher MD, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD, Mrózek K
|
|
|
J Clin Invest 117(9): 2408-21, 2008
|
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
|
|
Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, Liu S, Trotta R, Muthusamy N, Gambacorti-Passerini C, Druker BJ, Cortes J, Marcucci G, Chen CS, Verrills NM, Roy DC, Caligiuri MA, Bloomfield CD, Byrd JC, Perrotti D
|
|
|
Blood 111(11): 5371-9, 2008
|
|
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
|
|
Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD
|
|
|
J Natl Compr Canc Netw 6(6): 594-622, 2008
|
|
Hodgkin disease/lymphoma.
|
|
Hoppe RT, Advani RH, Ambinder RF, Bierman PJ, Bloomfield CD, Blum K, Dabaja B, Djulbegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hudson MM, Kaminski MS, Love G, Maloney DG, Mansur D, Mauch PM, Moore JO, Schilder RJ, Weiss LM, Winter JN, Yahalom J, Zelenetz AD
|
|
|
J Clin Oncol 26(30): 4934-9, 2008
|
|
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.
|
|
Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, Kolitz JE, Powell BL, Moore JO, Stone RM, Anastasi J, Bloomfield CD, Larson RA
|
|
|
N Engl J Med 358(18): 1919-28, 2008
|
|
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
|
|
Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield CD
|
|
|
Blood 111(6): 3183-9, 2008
|
|
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.
|
|
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM
|
|
|
J Natl Compr Canc Netw 6(9): 902-26, 2008
|
|
Myelodysplastic syndromes.
|
|
Greenburg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P
|
|
|
J Clin Oncol 26(28): 4603-9, 2008
|
|
Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
|
|
Neubauer A, Maharry K, Mrozek K, Thiede C, Marcucci G, Paschka P, Mayer RJ, Larson RA, Liu ET, Bloomfield CD
|
|
|
J Clin Oncol 26(31): 5078-87, 2008
|
|
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
|
|
Marcucci G, Maharry K, Radmacher MD, Mrózek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD
|
|
|
Blood 111(9): 4797-808, 2008
|
|
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
|
|
Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont D, McLellan MD, Payton JE, Westervelt P, Dipersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ
|
|
|
J Rural Health 24(1): 84-90, 2008
|
|
Tobacco use among the Amish in Holmes County, Ohio.
|
|
Ferketich AK, Katz ML, Kauffman RM, Paskett ED, Lemeshow SA, Westman JA, Clinton SK, Bloomfield CD, Wewers ME
|
|
|
Blood 112(5): 1646-54, 2008
|
|
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.
|
|
Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J
|
|
|
J Clin Oncol 26(28): 4595-602, 2008
|
|
Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
|
|
Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrozek K, Maharry K, Langer C, Baldus CD, Zhao W, Powell BL, Baer MR, Carroll AJ, Caligiuri MA, Kolitz JE, Larson RA, Bloomfield CD
|
|
|
